 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a...

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH  Get Free Report) has earned a consensus recommendation of Buy from the six analysts that are covering the firm, MarketBeat.com...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $14.60 Consensus PT from Brokerages

ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The...

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH Free Report) Stock analysts at HC Wainwright dropped their Q3 2023 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Wednesday, August 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company...

Q3 2023 Earnings Forecast for Reviva Pharmaceuticals Holdings, Inc. Issued By HC Wainwright (NASDAQ:RVPH)

- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Reviva ...

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY Research Report), Leg... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY Research Report), ...

Analysts Offer Insights on Healthcare Companies: Unicycive Therapeutics (UNCY), Legend Biotech (LEGN) and Reviva Pharmaceuticals Holdings (RVPH)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH Research Rep... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH Research ...

Analysts' Top Healthcare Picks: Reviva Pharmaceuticals Holdings (RVPH), Rani Therapeutics Holdings (RANI)

- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva ...

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast...

RedChip Launches 'Small Stocks, Big Money' Podcast

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Watchers	2,369
52-Wk Low	$1.56
52-Wk High	$9.25

Market Cap	$109.4M
Volume (M)	9,001.00
52-Wk High	$9.25
52-Wk Low	$1.56

RVPH Reviva Pharmaceuticals Holdings Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals